How to access Rivfloza from Saudi Arabia — the named-patient import pathway, 2026

Name: How to access Rivfloza from Saudi Arabia — the named-patient import pathway, 2026 | Reserve Meds
Published: 2026-04-23

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

A Saudi patient diagnosed with primary hyperoxaluria (PH) may receive a prescription for Rivfloza (nedosiran) from their treating nephrologist or metabolic-disease specialist, often at a Riyadh, Jeddah, or Eastern Province tertiary centre with a specialty paediatric-nephrology or adult-genetics service. Rivfloza is FDA-approved for primary hyperoxaluria type 1 and is developed by Novo Nordisk (acquired from Dicerna). PH is an ultra-rare inherited disorder, and routine stocking of Rivfloza through Saudi hospital pharmacies is not expected, so access runs through the Saudi Food and Drug Authority (SFDA) named-patient pathway.

This guide explains the legal pathway, the documentation your physician prepares, typical timing, indicative cost posture, and where Reserve Meds fits in.

The clinical situation

Rivfloza is a subcutaneous small interfering RNA (siRNA) therapy that reduces hepatic oxalate production by targeting LDHA, the enzyme at the final step of oxalate synthesis. It is administered once monthly by subcutaneous injection after in-clinic training, and is suitable for self-administration or caregiver administration. Eligibility requires biochemical and genetic confirmation of primary hyperoxaluria consistent with the labelled population, a documented elevation in urinary oxalate, and specialist-led management. Your nephrologist will establish baseline 24-hour urinary oxalate (or spot oxalate:creatinine ratio for younger patients), plasma oxalate where relevant, eGFR, renal imaging, and a long-term follow-up cadence.

Is Rivfloza legally importable into Saudi Arabia?

Yes — through the SFDA named-patient import framework. The SFDA named-patient route allows a Saudi-licensed physician to request import of a medicine not locally registered when (a) the medicine has been approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent locally registered alternative suits the patient, (c) the treating physician takes clinical responsibility for use, and (d) the importing party documents chain of custody. Primary hyperoxaluria has no clinically equivalent registered disease-modifying alternative on Saudi formularies, which supports clinical rationale.

How the pathway works, step by step

Consultation with your treating nephrologist or metabolic-disease specialist. Biochemical and genetic workup, urinary oxalate measurement, and a clinical rationale letter.
Baseline assessment. 24-hour urinary oxalate or spot oxalate:creatinine ratio, eGFR, renal ultrasound, plasma oxalate where relevant, and — critically — confirmation of genetic subtype.
SFDA named-patient application. The physician or hospital pharmacy files clinical rationale, patient reference, dosing plan (monthly SC), and chain-of-custody commitment.
US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Rivfloza from authorised distribution under DSCSA.
Cold-chain shipment. Rivfloza requires refrigerated handling; shipment follows validated cold-chain protocols with temperature logging.
Arrival, dispensing, and injection training. The hospital pharmacy releases product; the nephrology clinic provides self-injection training and sets the monthly schedule.

What documentation your physician needs

Clinical rationale letter confirming primary hyperoxaluria and Rivfloza as the indicated therapy
Verification of Saudi medical licence (SCFHS / MOH)
Genetic test result confirming PH subtype (AGXT for PH1)
Baseline 24-hour urinary oxalate or spot oxalate:creatinine ratio
Baseline eGFR, renal ultrasound, plasma oxalate where relevant
Patient weight and age
Planned dosing schedule (monthly SC) and long-term monitoring plan

Reserve Meds provides a physician documentation kit bundling the templates SFDA reviewers expect for ultra-rare nephrology / metabolic named-patient imports.

Costs and timing

Rivfloza for primary hyperoxaluria is a substantial ultra-rare-disease therapy. Reference US cash-pay for a full annual course (monthly subcutaneous dosing) typically sits in the mid-to-high six-figure USD range. Reserve Meds operates on a drug-only reference basis and provides a transparent, itemised delivered quote — covering product, cold-chain logistics, SFDA documentation handling, customs clearance, and concierge coordination — at the start of intake. Figures are indicative, not a binding quote until intake is complete.

Indicative timing — not guaranteed — for first dispense after cohort intake opens is approximately 7–14 days from the moment a complete SFDA application is submitted. Monthly refill cadence is established with the hospital pharmacy thereafter.

Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.

A culturally-aware note: primary hyperoxaluria is autosomal-recessive, and consanguinity patterns in some Saudi families mean multiple siblings may carry disease. Our concierge coordinates with the extended family when more than one patient in the household is under care.

Reserve Meds's role

Sourcing. Through our US-licensed specialty wholesale partner under DSCSA chain-of-custody.
Documentation. Regulatory package for your physician and SFDA review.
Logistics. Validated cold-chain shipment to your prescribing hospital pharmacy.
Concierge case lead. A named point of contact coordinating monthly refills.

What we do not do: We are not the prescriber. We do not practise medicine. We are not the dispensing pharmacy. All clinical decisions remain with your treating nephrologist or metabolic-disease specialist. We operate on a waitlist basis during pre-launch.

Frequently asked

Is this legal in Saudi Arabia? Yes, when executed through the SFDA named-patient framework with appropriate documentation. See our trust and compliance page.

How is Rivfloza different from Oxlumo? Both are siRNA therapies targeting oxalate overproduction in primary hyperoxaluria but act on different molecular targets (Rivfloza targets LDHA; Oxlumo targets HAO1). Labelled populations and dosing schedules differ. Your specialist selects based on genetic subtype, age, and clinical picture.

Does Rivfloza cure PH? No disease-modifying therapy is curative in primary hyperoxaluria, but Rivfloza substantially reduces urinary oxalate and can slow progression of renal damage. Transplant considerations remain individualised.

Will private insurance cover this? Cash-pay is the default. Some Saudi private insurers reimburse ultra-rare-disease imports on a case-by-case basis; we supply documentation for your submission but do not process insurance claims directly.

Next step — join the first-cohort waitlist

Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we enter intake for Rivfloza coordination in Saudi Arabia.

Add me to the Rivfloza waitlist

Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are in pre-launch; service availability is limited to our first cohort and published timelines are indicative, not guarantees. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.

Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.